Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes - PubMed (original) (raw)

Review

. 2004 Aug 12;47(17):4128-34.

doi: 10.1021/jm030630m.

Affiliations

• PMID: 15293981
• DOI: 10.1021/jm030630m

Review

Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes

Lotte Bjerre Knudsen. J Med Chem. 2004.

No abstract available

PubMed Disclaimer

Similar articles

• The potential role of glucagon-like peptide 1 in diabetes.
  Meier JJ, Nauck MA. Meier JJ, et al. Curr Opin Investig Drugs. 2004 Apr;5(4):402-10. Curr Opin Investig Drugs. 2004. PMID: 15134281 Review.
• Novel "second-generation" approaches for the control of type 2 diabetes.
  Rotella DP. Rotella DP. J Med Chem. 2004 Aug 12;47(17):4111-2. doi: 10.1021/jm030626a. J Med Chem. 2004. PMID: 15293978 No abstract available.
• [A therapeutic option for type-2 diabetes. The incretion hormone GLP-1].
  Göke B, Hoppe B, Konrad A, Schirra J. Göke B, et al. Pharm Unserer Zeit. 2002;31(3):294-9. doi: 10.1002/1615-1003(200205)31:3<294::AID-PAUZ294>3.0.CO;2-1. Pharm Unserer Zeit. 2002. PMID: 12071126 Review. German. No abstract available.
• Theratechnologies expands peptide portfolio in endocrinology.
  Walczak IM. Walczak IM. Diabetes Technol Ther. 2002;4(5):734. Diabetes Technol Ther. 2002. PMID: 12458565 No abstract available.
• Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.
  Holst JJ, Deacon CF. Holst JJ, et al. Curr Opin Pharmacol. 2004 Dec;4(6):589-96. doi: 10.1016/j.coph.2004.08.005. Curr Opin Pharmacol. 2004. PMID: 15525549 Review.

Cited by

• Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes.
  Gough SC, Jain R, Woo VC. Gough SC, et al. Expert Rev Endocrinol Metab. 2016 Jan 2;11(1):7-19. doi: 10.1586/17446651.2016.1113129. Epub 2015 Nov 18. Expert Rev Endocrinol Metab. 2016. PMID: 27335581 Free PMC article.
• A review on the synthesis of heteroannulated quinolones and their biological activities.
  Elshaier YAMM, Aly AA, El-Aziz MA, Fathy HM, Brown AB, Ramadan M. Elshaier YAMM, et al. Mol Divers. 2022 Aug;26(4):2341-2370. doi: 10.1007/s11030-021-10332-1. Epub 2021 Oct 26. Mol Divers. 2022. PMID: 34698911 Review.
• Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage.
  Hou J, Manaenko A, Hakon J, Hansen-Schwartz J, Tang J, Zhang JH. Hou J, et al. J Cereb Blood Flow Metab. 2012 Dec;32(12):2201-10. doi: 10.1038/jcbfm.2012.133. Epub 2012 Sep 12. J Cereb Blood Flow Metab. 2012. PMID: 22968320 Free PMC article.
• Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.
  Mannino GC, Sesti G. Mannino GC, et al. Mol Diagn Ther. 2012 Oct;16(5):285-302. doi: 10.1007/s40291-012-0002-7. Mol Diagn Ther. 2012. PMID: 23018631 Review.
• Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?
  Li L. Li L. Neurosci Bull. 2007 Jan;23(1):58-65. doi: 10.1007/s12264-007-0009-y. Neurosci Bull. 2007. PMID: 17592527 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Chemical Society

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information